Pharmacologic Therapies for Patent Ductus Arteriosus in Extremely Preterm Infants

What is the relative effectiveness of different pharmacotherapeutic regimens for patent ductus arteriosus (PDA) in extremely preterm infants?In this comparative effectiveness study of 1356 extremely preterm infants (born before 29 weeks’ gestation), the overall primary PDA pharmacotherapy failure rate was 42.3%. There were no differences between 4 treatment regimens in failure of primary pharmacotherapy or need for repeat treatment, after adjustment for confounders and accounting for clustering within each participating neonatal intensive care unit.In this study, no observed differences in effectiveness of primary PDA pharmacotherapy were found in extremely preterm infants regardless of medication choice.

Corresponding Author: Souvik Mitra, MD, MSc, PhD, University of British Columbia, 4500 Oak St, Room 1N53, Vancouver, BC V6H 3N1, Canada (souvik.mitra@cw.bc.ca; souvik.mitra@ubc.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.